Fosun Pharma: Subsidiary's Androgenetic Alopecia Novel Drug LBP-ShC4 Approved for Clinical Trial, No Similar Products on Market Globally

2026-03-17 07:55:08

Recently, Fosun Pharma announced that its controlling subsidiary, Junji Health, received approval from the National Medical Products Administration to conduct clinical trials of LBP-ShC4. Junji Health plans to initiate Phase I clinical research of LBP-ShC4 in China once conditions are met.

LBP-ShC4 is an in-house developed live biological therapy product primarily used to treat androgenetic alopecia (AGA). In May 2025, clinical trials for this indication received approval from the U.S. Food and Drug Administration (FDA).

As of February 2026, the company’s total R&D investment in LBP-ShC4 was approximately 20 million yuan (unaudited). Currently, no live biological therapy products for the treatment of androgenetic alopecia have been approved for market launch worldwide.

(Fosun Pharma Announcement)

(Edited by: Yang Yan, Lin Chen)

Keywords: Medical

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.